



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Grant Number: 1R01AI129745-01A1
FAIN: R01AI129745

Principal Investigator(s):
Siddappa N Byrareddy (contact), PHD
Mirko Paiardini, PHD

Project Title: Limiting HIV establishment and maintenance by preserving intestinal immunity

Vetter, Deborah K
Director, Sponsored Programs
987835 Nebraska Medical Center
Omaha, NE 681987835

Award e-mailed to: spadmin@unmc.edu

Period Of Performance:
Budget Period: 04/01/2017 – 03/31/2018
Project Period: 04/01/2017 – 03/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$847,715 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEBRASKA MEDICAL CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI129745. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Michael W. Fato
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows



Grant Number: 1R01AI113883-01 REVISED
FAIN: R01AI113883

Principal Investigator(s):
Siddappa N Byrareddy, PHD

Project Title: Role of HIV Env glycosylation in mucosal transmission

Aaronette Floyd
Director, Pre-award Grants Adm
1599 Clifton Road NE, 4th Floor
1599-001-1BA
Atlanta, GA 303224250

Award e-mailed to: osp@emory.edu

Period Of Performance:
Budget Period: 07/16/2014 – 06/30/2015
Project Period: 07/16/2014 – 06/30/2019

Dear Business Official:

The National Institutes of Health hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to EMORY UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI113883. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Laura C. Eisenman
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows



NATIONAL INSTITUTE ON DRUG ABUSE

Grant Number: 1R01DA052845-01
FAIN: R01DA052845

Principal Investigator(s):
Siddappa N Byrareddy, PHD
Mahesh Mohan (contact), DVM

Project Title: Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection

Esquivel, Juan
Sponsored Programs Administrator
8715 W Military Dr
San Antonio, TX 782275302

Award e-mailed to: grants@txbiomed.org

Period Of Performance:
Budget Period: 09/30/2020 – 06/30/2021
Project Period: 09/30/2020 – 06/30/2025

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$730,433 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to Texas Biomedical Research Institute in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R01DA052845. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Amy Connolly
Grants Management Officer
NATIONAL INSTITUTE ON DRUG ABUSE

Additional information follows



NATIONAL INSTITUTE OF MENTAL HEALTH

Grant Number: 1R21MH113455-01
FAIN: R21MH113455

Principal Investigator(s):
Siddappa N Byrareddy, PHD

Project Title: Targeting gut-brain axis to eliminate CNS reservoirs

Deborah Vetter
University of Nebraska Medical Center
987835 Nebraska Medical Center
Omaha, NE 681987835

Award e-mailed to: spadmin@unmc.edu

Period Of Performance:

Budget Period: 05/01/2017 – 04/30/2018

Project Period: 05/01/2017 – 04/30/2019

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$225,750 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEBRASKA MEDICAL CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R21MH113455. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Jane Z. Lin
Grants Management Officer
NATIONAL INSTITUTE OF MENTAL HEALTH

Additional information follows